Pattern of response of the main MC symptoms after rituximab therapy
| Patient no. . | Sex . | Skin ulcers . | Purpura . | Neuropathic pain . | Paresthesias . | Nephritis . | Arthralgias . |
|---|---|---|---|---|---|---|---|
| 1 | F | NA | NA | MR (< 6) | MR (< 6) | NA | NA |
| 2 | F | NA | MR (EOT) | MnR | MR (< 1) | NA | CR (< 1) |
| 3 | F | CR (< 1) | MR (< 3)* | NR | NR | PR | PR |
| 4 | F | NA | MR (< 3) | MR (< 6) | MR (< 6) | PR | CR (< 1) |
| 5 | F | NA | MR (< 6) | MR (< 6) | CR (< 1) | NA | CR (< 1) |
| 6 | M | NA | MR (< 3) | CR (< 1) | CR (< 1) | PR | NA |
| 7 | F | NA | MR (< 6) | MnR | CR (< 1) | NA | PR |
| 8 | M | NA | MR (< 3) | MR (< 6) | MnR | CR (< 2) | CR (< 1) |
| 9 | F | NA | MR (< 3) | MR (< 6) | MnR | NA | PR |
| 10 | F | NA | MR (< 3) | NR | NR | NA | PR |
| 11 | M | NA | MnR | MR (< 6) | NR | NA | NA |
| 12 | M | NA | MnR | CR (< 1) | MnR | NA | PR |
| 13 | F | NA | NA | CR (< 1) | CR (< 1) | NA | CR (< 1) |
| 14 | M | NA | MR (< 6) | NA | NA | NA | NA |
| 15 | M | MR (< 1) | MR (< 6) | MR (< 6) | MR (< 6) | CR (< 6) | PR |
| 16 | F | NA | MR (< 6) | MR (< 6) | NR | NA | CR (< 1) |
| 17 | F | NA | MR (< 6) | MnR | MnR | NA | PR |
| 18 | F | CR (< 1) | MnR | NR | NR | NA | CR (< 1) |
| 19 | F | NA | MR (EOT) | NR | CR (< 1) | NA | PR |
| Patient no. . | Sex . | Skin ulcers . | Purpura . | Neuropathic pain . | Paresthesias . | Nephritis . | Arthralgias . |
|---|---|---|---|---|---|---|---|
| 1 | F | NA | NA | MR (< 6) | MR (< 6) | NA | NA |
| 2 | F | NA | MR (EOT) | MnR | MR (< 1) | NA | CR (< 1) |
| 3 | F | CR (< 1) | MR (< 3)* | NR | NR | PR | PR |
| 4 | F | NA | MR (< 3) | MR (< 6) | MR (< 6) | PR | CR (< 1) |
| 5 | F | NA | MR (< 6) | MR (< 6) | CR (< 1) | NA | CR (< 1) |
| 6 | M | NA | MR (< 3) | CR (< 1) | CR (< 1) | PR | NA |
| 7 | F | NA | MR (< 6) | MnR | CR (< 1) | NA | PR |
| 8 | M | NA | MR (< 3) | MR (< 6) | MnR | CR (< 2) | CR (< 1) |
| 9 | F | NA | MR (< 3) | MR (< 6) | MnR | NA | PR |
| 10 | F | NA | MR (< 3) | NR | NR | NA | PR |
| 11 | M | NA | MnR | MR (< 6) | NR | NA | NA |
| 12 | M | NA | MnR | CR (< 1) | MnR | NA | PR |
| 13 | F | NA | NA | CR (< 1) | CR (< 1) | NA | CR (< 1) |
| 14 | M | NA | MR (< 6) | NA | NA | NA | NA |
| 15 | M | MR (< 1) | MR (< 6) | MR (< 6) | MR (< 6) | CR (< 6) | PR |
| 16 | F | NA | MR (< 6) | MR (< 6) | NR | NA | CR (< 1) |
| 17 | F | NA | MR (< 6) | MnR | MnR | NA | PR |
| 18 | F | CR (< 1) | MnR | NR | NR | NA | CR (< 1) |
| 19 | F | NA | MR (EOT) | NR | CR (< 1) | NA | PR |
Values reported are timing of response (in months after EOT).
F indicates female; M, male; NA, not applicable; MR, major response; EOT, end of treatment; MnR, minor response; CR, complete response; NR, no response; and PR, partial response.
This patient had a relapse 6 months after EOT.